Eli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk

The FDA approved Eli Lilly's Mounjaro (tirzepatide) to reduce the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk, marking it as the first drug in its class with this indication after demonstrating an 8% lower rate of major cardiovascular events compared to Lilly's older drug Trulicity.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.